The current hypothesis is that optimal cancer-specific CTL function is determined by antigen sensitivity, which is influenced by T-cell receptor (TCR) affinity to different tumor antigens peptide loaded onto MHC class Ia molecules and/or nonclassical MHC class Ib molecules, such as HLA-E. Here, HLA-E is linked to cancer.